Amylyx Pharmaceuticals reported a third-quarter net loss of $45.5 million, or $0.38 per share, compared to a $34.4 million loss in the prior-year period. Research and development expenses rose to $28.4 million due to increased spending on the pivotal Phase 3 LUCIDITY clinical trial for avexitide, while selling, general and administrative expenses increased to $21.3 million. The company highlighted positive topline results from the LUCIDITY trial, which met its primary endpoint with a 55% reduction in severe hypoglycemic events compared to placebo. Additionally, Amylyx announced it has approximately $768.1 million in cash and marketable securities following an equity offering that raised net proceeds of roughly $544.6 million. The company remains on track to submit a New Drug Application for avexitide by the end of 2026. Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for rare diseases with high unmet needs.
